Genomic variants exclusively identified in children with birth defects and concurrent malignant tumors predispose to cancer development.
Birth defects
Pediatric cancer development
Sequencing
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
05 08 2023
05 08 2023
Historique:
received:
16
05
2023
accepted:
18
07
2023
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
epublish
Résumé
Children with birth defects (BD) express distinct clinical features that often have various medical consequences, one of which is predisposition to the development of cancers. Identification of the underlying genetic mechanisms related to the development of cancer in BD patients would allow for preventive measures. We performed a whole genome sequencing (WGS) study on blood-derived DNA samples from 1566 individuals without chromosomal anomalies, including 454 BD probands with at least one type of malignant tumors, 767 cancer-free BD probands, and 345 healthy individuals. Exclusive recurrent variants were identified in BD-cancer and BD-only patients and mapped to their corresponding genomic regions. We observed statistically significant overlaps for protein-coding/ncRNA with exclusive variants in exons, introns, ncRNAs, and 3'UTR regions. Exclusive exonic variants, especially synonymous variants, tend to occur in prior exons locus in BD-cancer children. Intronic variants close to splicing site (< 500 bp from exon) have little overlaps in BD-cancer and BD-only patients. Exonic variants in non-coding RNA (ncRNA) tend to occur in different ncRNAs exons regardless of the overlaps. Notably, genes with 5' UTR variants are almost mutually exclusive between the two phenotypes. In conclusion, we conducted the first genomic study to explore the impact of recurrent variants exclusive to the two distinguished clinical phenotypes under study, BD with or without cancer, demonstrating enrichment of selective protein-coding/ncRNAs differentially expressed between these two phenotypes, suggesting that selective genetic factors may underlie the molecular processes of pediatric cancer development in BD children.
Identifiants
pubmed: 37543594
doi: 10.1186/s12943-023-01828-5
pii: 10.1186/s12943-023-01828-5
pmc: PMC10403830
doi:
Types de publication
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Biochem Biophys Rep. 2022 Jun 28;31:101301
pubmed: 35800618
Trends Cancer. 2019 Apr;5(4):245-262
pubmed: 30961831
Biomark Res. 2022 Nov 16;10(1):84
pubmed: 36384586
Nat Commun. 2019 Jun 12;10(1):2569
pubmed: 31189880
Nat Commun. 2018 Dec 14;9(1):5330
pubmed: 30552315
JAMA Oncol. 2019 Aug 01;5(8):1150-1158
pubmed: 31219523
Signal Transduct Target Ther. 2021 Jan 1;6(1):2
pubmed: 33384409
Nat Med. 2004 Aug;10(8):789-99
pubmed: 15286780
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
J Med Genet. 2005 Oct;42(10):737-48
pubmed: 16199547
BMC Cancer. 2017 Dec 28;17(1):901
pubmed: 29282011
Semin Cell Dev Biol. 2020 Feb;98:44-53
pubmed: 31176736
Oncogene. 2021 Feb;40(7):1347-1361
pubmed: 33420369
Proc Natl Acad Sci U S A. 2022 Sep 13;119(37):e2203738119
pubmed: 36067288
Hormones (Athens). 2020 Sep;19(3):403-412
pubmed: 32592099